Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
about
Current Trends of Renal Impairment in Multiple MyelomaBortezomib in patients with renal impairment.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case reportBortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.Multiple Myeloma: Treatment is Getting IndividualizedCurrent therapy of myeloma induced renal failure.Bortezomib in the front-line treatment of multiple myeloma.Kidney disease associated with plasma cell dyscrasiasThe Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Guidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Multiple myeloma: biology, standard therapy, and transplant therapy.A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010.Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
P2860
Q26740444-311A8693-AEA6-400C-AAA3-F227BE5B1441Q33396250-888FC01C-CA32-45D6-923D-323CDB9A082CQ33407105-AF390077-14C4-452D-93C9-B83EC9107D82Q34228650-8634C0AF-2CCE-446F-93FE-CD7A1CAE1E8BQ36196981-4308ECF4-72E1-4417-AC7B-196FFEF17429Q36522964-76B5B10C-0A78-41D9-8745-5B0F0F8424F3Q37152741-F2B45BB6-1AA7-4658-A062-1D0DB0A8E673Q37202761-0F9312FE-83BE-4D22-8BE0-72251642F35FQ37750106-C32A3B40-5BF5-4C0A-A1B1-0E0667FB80A3Q37800884-C8C9DCFA-D871-495B-8295-EBAEC7202D40Q37875193-23619EC8-769F-4E51-9D5D-3BD680146090Q37903590-8F9C7BAF-4530-47EE-9C72-C433BBC405C7Q37978343-B4974CA4-D4CC-49FA-A07F-F88815254B68Q37986358-BFC89212-8AF8-43B2-8776-986DBE1DCD24Q38109235-7F67D883-0946-4AAA-B55A-4320D076EC2FQ38122674-3BBEA112-D47C-4245-8EB2-4C425DE8B909Q38976968-C939DA88-8062-4E44-AED4-F76B929821D5Q42794048-673C868C-9EB6-4FF8-9F60-C68265A51E60Q45328412-CCA5DACD-2B43-4CB5-B324-5EA4BDEDC100Q45892519-B4EB4427-4993-4699-BEC0-95300E3D6121Q47562792-D9637874-F05C-4DCD-BEBE-30607A89BBBAQ50973983-D4BD2E22-1420-4735-AFA1-417C6E9072C4Q53173592-BC464012-E164-430F-9D24-0F99BF2895FDQ57904432-B2AEA552-74CF-4149-8E5F-5916C9CA5755
P2860
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of patients with mul ...... ith bortezomib-based regimens.
@en
Treatment of patients with mul ...... ith bortezomib-based regimens.
@nl
type
label
Treatment of patients with mul ...... ith bortezomib-based regimens.
@en
Treatment of patients with mul ...... ith bortezomib-based regimens.
@nl
prefLabel
Treatment of patients with mul ...... ith bortezomib-based regimens.
@en
Treatment of patients with mul ...... ith bortezomib-based regimens.
@nl
P2093
P2860
P1433
P1476
Treatment of patients with mul ...... ith bortezomib-based regimens.
@en
P2093
Charis Matsouka
Despina Barmparousi
Erasmia Psimenou
Evangelos Terpos
Irini Grapsa
Magdalini Migkou
Maria Roussou
P2860
P304
P356
10.1080/10428190801930506
P577
2008-05-01T00:00:00Z